Sutro Biopharma Toekomstige groei
Future criteriumcontroles 2/6
De verwachting is dat Sutro Biopharma de winst en omzet met respectievelijk 2.8% en 24% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 12.1% per jaar.
Belangrijke informatie
2.8%
Groei van de winst
12.1%
Groei van de winst per aandeel
Biotechs winstgroei | 26.9% |
Inkomstengroei | 24.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 20 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
Oct 11Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 66 | -290 | -177 | -256 | 9 |
12/31/2025 | 58 | -280 | -219 | -238 | 11 |
12/31/2024 | 69 | -228 | -187 | -171 | 11 |
6/30/2024 | 169 | -124 | -78 | -75 | N/A |
3/31/2024 | 154 | -115 | -119 | -115 | N/A |
12/31/2023 | 154 | -107 | -116 | -112 | N/A |
9/30/2023 | 49 | -172 | -156 | -150 | N/A |
6/30/2023 | 57 | -143 | -57 | -50 | N/A |
3/31/2023 | 75 | -130 | -29 | -22 | N/A |
12/31/2022 | 68 | -119 | -4 | 4 | N/A |
9/30/2022 | 70 | -123 | -1 | 6 | N/A |
6/30/2022 | 53 | -134 | -96 | -84 | N/A |
3/31/2022 | 53 | -114 | -101 | -87 | N/A |
12/31/2021 | 62 | -106 | -97 | -82 | N/A |
9/30/2021 | 60 | -127 | -93 | -79 | N/A |
6/30/2021 | 69 | -79 | -85 | -72 | N/A |
3/31/2021 | 50 | -43 | -88 | -79 | N/A |
12/31/2020 | 43 | -32 | -75 | -68 | N/A |
9/30/2020 | 46 | 13 | -70 | -62 | N/A |
6/30/2020 | 40 | -17 | -66 | -61 | N/A |
3/31/2020 | 41 | -61 | -68 | -64 | N/A |
12/31/2019 | 43 | -56 | -69 | -65 | N/A |
9/30/2019 | 51 | -42 | -60 | -58 | N/A |
6/30/2019 | 46 | -40 | 4 | 6 | N/A |
3/31/2019 | 41 | -38 | 6 | 8 | N/A |
12/31/2018 | 38 | -35 | 11 | 13 | N/A |
9/30/2018 | 23 | -49 | 12 | 14 | N/A |
6/30/2018 | 33 | -40 | -38 | -36 | N/A |
3/31/2018 | 42 | -30 | N/A | -37 | N/A |
12/31/2017 | 52 | -20 | N/A | -37 | N/A |
12/31/2016 | 60 | N/A | N/A | -13 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat STRO de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat STRO de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat STRO de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van STRO ( 24% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van STRO ( 24% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van STRO naar verwachting over 3 jaar hoog zal zijn